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Abstract
Background: Endometriosis affects 6–10% of women and is associated with debilitating pelvic pain. It costs the
UK > £2.8 billion per year in loss of productivity. Endometriosis can be managed by surgical excision or medically
by ovarian suppression. However, ~ 75% symptoms recur after surgery and available medical treatments have
undesirable side effects and are contraceptive. Omega-3 purified fatty acids (PUFA) have been shown in animal
models to reduce factors that are thought to lead to endometriosis-associated pain, have minimal side effects, and
no effects on fertility. This paper presents a protocol for a two-arm, pilot parallel randomised controlled trial (RCT)
which aims to inform the planning of a future multicentre trial to evaluate the efficacy of Omega-3 PUFA in the
management of endometriosis-associated pain in women.
Methods: The study will recruit women with endometriosis over a 12-month period in the National Health Service
(NHS) Lothian, UK, and randomise them to 8 weeks of treatment with Omega-3 PUFA or comparator (olive oil). The
primary objective is to assess recruitment and retention rates. The secondary objectives are to determine the
effectiveness/acceptability to participants of the proposed methods of recruitment/randomisation/treatments/
questionnaires, to inform the sample size calculation and to refine the research methodology for a future large
randomised controlled trial. Response to treatment will be monitored by pain scores and questionnaires assessing
physical and emotional function compared at baseline and 8 weeks.
Discussion: We recognise that there may be potential difficulties in mounting a large randomised controlled trial
for endometriosis to assess Omega-3 PUFA because they are a dietary supplement readily available over the counter
and already used by women with endometriosis. We have therefore designed this pilot study to assess practical feasibility
and following the ‘Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials’ recommendations for the
design of chronic pain trials.
Trial registration: ISRCTN44202346
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Background
Endometriosis is an inflammatory condition that affects
6–10% of women in the UK [1] and is responsible for
approximately 20% of gynaecological consultations. It is
associated with chronic pelvic pain, pain during men-
struation, pain during intercourse, and an increased like-
lihood of infertility [2]. Endometriosis is associated with
a 45% reduction in work productivity with the annual
cost for caring for women with endometriosis estimated
at > £2.8 billion in the UK [1].
Endometriosis is defined by the presence of
endometrial-like tissue (endometriosis ‘lesions’) outside
the uterine cavity, most commonly on the pelvic periton-
eum or ovaries [2]. The cause of the painful symptoms
experienced by women with endometriosis is not well
understood. Endometriosis is treated by surgical excision
or medical management by ovarian suppression. However,
up to 75% symptoms recur after surgery and medical
treatments have undesirable side effects [3] and are
contraceptive. There is an unmet need for new medical
treatments for endometriosis.
An ideal therapy for endometriosis would (i) reduce the
painful symptoms associated with the condition, (ii)
reduce lesion size, (iii) preserve the patients’ ability to
conceive while on medication, and (iv) have no, or limited,
side effects. Oral Omega-3 purified fatty acids (PUFA)
have the potential to meet all of the above criteria.
Omega-3 PUFA are a Food and Drug Administration
(FDA)-approved dietary supplement, which play a role in
the regulation of prostaglandin metabolism and cytokine
physiology, and are thought to work by competing with
Omega-6 PUFA to produce lipid mediators which are
anti-inflammatory as opposed to pro-inflammatory [4].
Intake of food with a high content of Omega-3 PUFA have
been used in other inflammatory conditions, such as
atherosclerosis, asthma, and rheumatoid arthritis and have
been shown to have an anti-inflammatory effect [5].
In endometriosis, Omega-3 PUFA supplementation has
been shown to reduce lesion size and reduce local prosta-
glandin/cytokine production in a rat model [6]. In an endo-
metriosis model using Fat-1 mice, in which Omega-6 can
be converted to Omega-3 PUFA, the number and weight of
endometriotic lesions 2 weeks after inoculation were signifi-
cantly less than in Fat-1 mice compared to controls who
cannot convert Omega-6 to Omega-3 PUFA [7]. In vitro
studies, using endometrium from women with and without
endometriosis have shown that Omega-3 PUFA might have
a suppressive effect on endometrial cell survival [8]. In a
large, prospective cohort study investigating dietary expos-
ure and endometriosis risk in women, it was concluded that
increasing Omega-3 PUFA intake might be the first identi-
fied modifiable risk factor for endometriosis [8]. Finally, it is
reported that a low ratio of Omega-3 to Omega-6 PUFA
intake is correlated with painful menstruation and a high
rate of autoimmune and endocrine disorders in women
with endometriosis [9].
We believe that it is important to determine the true
value of Omega-3 PUFA for the control of or potential
elimination of endometriosis-associated pain. A definitive
evaluation of the efficacy of Omega-3 PUFA in the
management of endometriosis-associated pain will require
a large, multicentre randomised controlled trial. This
protocol outlines a pilot study to assess the processes that
are unknown and vital to the delivery of such a trial,
including variance of the response, variables for sample
size calculation, follow-up rates, and ‘failure to comply
with treatment’ rates. In the pilot study, we are using olive
oil capsules, which do not contain Omega-3 PUFA, as a
comparator due to lack of availability of a matched
placebo. We accept that this comparator might have the
potential for pain relief which could encourage participa-
tion in our trial and that it might have a unique taste with
a theoretical risk of unblinding the trial medication.
Methods/design
Study design
We aim to perform a two-arm, parallel, double blind
randomised controlled pilot trial (Fig. 1).
Study settings
We will recruit patients from gynaecology outpatient
clinics, gynaecology wards and day surgery units within
NHS Lothian, UK (Royal Infirmary of Edinburgh and St.
John’s Hospital).
Study participants
Women with a surgical diagnosis of endometriosis and
associated pelvic pain will be recruited.
Primary objective
The primary objective is to assess recruitment and
retention rates. Recruitment is defined as the proportion
of eligible patients who agreed to participate from the
number approached. Whereas retention is defined as the
proportion of the participating patients who completed
both baseline and follow-up visits.
Secondary objectives
1. Estimation of variability of responses for sample
size calculation
2. Acceptability of proposed methods of recruitment,
randomisation, treatments and questionnaires
Inclusion criteria
Women are eligible for inclusion if they are as follows:
 Aged between 18 and 50 years.
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 Pelvic pain of > 3 months
 Pain located within the true pelvis
 Endometriosis diagnosed macroscopically
by laparoscopy
 A numerical rating average ‘worst’ pain score
(NRS) of greater than or equal (≥) to four
(see below for details).
Exclusion criteria
Women are excluded if they have one or more of the
following:
 Unable to take/allergic to fish/PUFA/peanuts/soyabean
 Insulin-dependent diabetes
 Pregnancy
 Taking anticoagulants
 Breast feeding
 Unable to give informed consent
Co-primary outcomes
 Recruitment and retention rates
Secondary outcomes
 Estimation of variability of responses to inform the
primary outcome of the future definitive RCT
 Acceptability of proposed methods of recruitment,
randomisation, treatments, and questionnaires
Participant enrolment
All gynaecology consultants within NHS Lothian will be sent
an email informing them of the study and requesting permis-
sion to approach their patients. A clinical research fellow will
approach eligible women who have agreed to be seen by the
trial team, while the women are still in the clinic, provide
them with patient information sheets and offer them the
opportunity to discuss the trial. Consent will only be taken
later once the patient has had ample time, of at least 24 h, to
read the patient information sheet. A further appointment
will be arranged for the participant to come for this visit.
Screening
Eligibility for randomisation will be based on the worst of
four weekly numerical rating scale (0–10; NRS) pain scores
Fig. 1 Flow chart for the trial process
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collected by text messaging (‘run-in phase’), score of 4 out
of 10 in 2 or more weeks is required. Texts will be sent by
the clinical research fellow to the women’s mobile phone,
asking about average and worst pain, respectively, and the
woman will be asked to reply to the text message with her
pain score, rating it from 0 for no pain at all, to 10 being
worst pain imaginable. To capture known cyclicity in pain
in women, these texts will be sent once per week during
the eligibility phase (weeks–minus one to minus four). If a
woman has an NRS of greater than or equal to ≥ 4 in two
or more of the pre-randomisation run-in weeks of the
study, she will be eligible for randomisation.
Intervention
Women will be randomised to one capsule of Omacor
1000 mgs capsules (Omega-3-acid ethyl ester filled cap-
sules) or one capsule of comparator (olive oil soft gelatin
capsules which do not contain Omega-3 PUFA) to be
taken twice a day, once in the morning and once at night
with food. The allocated treatments will be taken for
8 weeks. Omega-3 purified fatty acids have been used clin-
ically, e.g. post myocardial infarction and for hypertriglyc-
eridemia at doses of 1000–4000 mg daily (in divided doses
of 1000 or 2000 mg) [10]. However, high dosage (i.e.
4000 mg) has been associated with a moderate increase in
bleeding time [11], so we chose to pilot a lower dose and
frequency of one capsule (1000 mg) twice a day. We
approached the MHRA for advice, and due to the fact that
both PUFA and olive oil are ‘food supplements’, our trial
was not deemed a CTIMP.
Randomisation
The randomisation scheme will be generated using tables,
drawn up by an independent statistician, with 1:1 alloca-
tion ratio. The allocated treatment codes will be put into
sealed consecutively numbered opaque envelopes. When a
woman is randomised into the study, she will receive the
treatment indicated in the next available envelope.
Data collection tools
Pain scores
During the treatment phase of the study, pain scores will
be collected once a week by text messaging during last
4 weeks of the treatment phase (weeks 5 to 8) using the
same study procedures as during the ‘run-in phase’.
Questionnaires
Women will be given the questionnaires below to complete
at baseline and 8 weeks. Baseline demographic and clinical
characteristics of the participants will also be recorded at
baseline.
1. Brief Pain Inventory (BPI) [12]
2. 12-Item Short-Form Health Survey (SF-12) [13]
3. Pain Catastrophizing Questionnaire (PCQ) [14]
4. Pain DETECT™ [15]
5. Sexual Activity Questionnaire (SAQ) [16]
6. Brief Fatigue Inventory (BFI) [17]
7. General Health Questionnaire-12 (GHQ-12) [18]
8. Work and Productivity Impairment
Questionnaire-specific Health Problem
Version 2.0 (WPAI-SHP) [19]
An additional acceptability questionnaire will be com-
pleted at the end of the study only. This questionnaire
will also include questions about whether participants
believed that they were receiving Omega-3 PUFA or
olive oil, the acceptability of the allocated medication/
treatment regimens (and compliance) and on the accept-
ability of completing trial-specific procedures including
the questionnaires. All questionnaires will be anonymised
and self-completed in private.
Treatment diaries
Participants will be provided with a treatment diary at the
same time as their medication pack is dispensed and
blood samples will be collect at baseline. All medications
other than the trial treatment taken during the treatment
phase of the study will be recorded in a treatment diary.
This will include prescription and non-prescription treat-
ment, such as oral analgesics, contraceptives, vitamins,
topical preparations and herbal preparations.
Participant log
We will keep an anonymised electronic log of women
who fulfil the eligibility criteria, women who are invited
to participate in the study, women recruited and women
who leave the trial early. Reasons for non-recruitment
(e.g. non-eligibility, refusal to participate, administrative
error) will also be recorded. We will attempt to collect
reasons for non-participation from women who decline
to take part after previously providing contact details.
During the course of the study, we will attempt to docu-
ment reasons for withdrawal from the study and loss to
follow-up.
Termination of study
The blinding code will only be broken in emergency situa-
tions for reasons of patient safety, where knowledge of the
treatment administered is necessary for the treatment of a
serious adverse event or when required by local regulatory
authorities. Participants whose randomisation codes are
broken will cease treatment, but will continue to be
followed up. The principal investigator will document the
reason for breaking the blind in the participant’s source
documents and in the Investigator Site Master File. If the
participant requires to be unblinded in an emergency,
then the research team or pharmacy should be contacted.
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Adverse events
Participants will collect information about adverse events
in their treatment diaries. They will also be instructed to
contact the clinical research fellow at any time after con-
senting to join the trial if they have an event that requires
hospitalisation or an event that results in persistent or
significant disability or incapacity. Omega-3 PUFA are an
FDA-approved dietary supplement, and serious adverse
events are not anticipated. Any serious adverse events that
occur after joining the trial will be reported in detail in the
participant’s medical notes, followed up until resolution of
the event and reported to the Academic and Clinical
Central Office for Research & Development (ACCORD)
Research Governance (http://www.accord.ed.ac.uk) and
Quality Assurance Office based at the University of Edin-
burgh immediately, or within 24 h. ACCORD will onward
report all serious adverse events (SAE) within 7 days.
Hospitalisation for a pre-existing condition, e.g. exacerba-
tion of pain due to endometriosis will not be considered a
SAE, but will be documented.
Sample size
The emphasis in this study is to establish feasibility, not
statistical significance. This study is designed primarily
to explore the recruitment and retention rates, and we
will aim to recruit as many women as possible over a
12-month period. We estimate that we will recruit ~ 4–5
patients per month and will aim to recruit 40 patients.
As we anticipate a recruitment rate of 50%, 40 partici-
pants would be able to give 95% confidence interval of
35–65%. The data from this pilot study will be used to
refine sample size calculations for any future RCT.
Data analysis
Recruitment and retention rates
Using the information collected from the participant log,
we will determine the number of patients recruited from
the pool of eligible women and a > 50% recruitment will
be deemed acceptable. While a retention rate of 100%
would be ideal, we will consider a rate of 80% satisfac-
tory. We will provide an estimate of the proportion and
its 95% confidence interval. In addition, we will deter-
mine the nature and number of unanswered questions
in each questionnaire. We aim to determine whether the
trial design will perform well enough in the field to
warrant rolling out the study to full trial. All analysis will
be carried out at the University of Edinburgh.
Effectiveness and acceptability of proposed methods of
recruitment, randomisation, treatments and assessment
tools
These areas will be assessed quantitatively using additional
questions included in participant questionnaires adminis-
tered at 8 weeks. The data collected from the different
questionnaires will be used to explore comparisons be-
tween the two groups and will be reported as estimates of
difference and corresponding confidence intervals in order
to calculate sample size. Due to the conflicting literature
about the benefits of methods such as prescription moni-
toring, pill counting and devices for monitoring the self-
administration of medicines, data on blinding and compli-
ance to treatment will be derived from questionnaires at
8 weeks. We aim to determine if treatment is acceptable
in terms of self-reported compliance (from treatment
diaries). We will examine the effect of non-compliance
and retention, which will be used to inform the sample
size required for a full trial.
Trial sponsors
The trial is co-sponsored by the University of Edinburgh
and NHS Lothian.
Data handling, storage and archiving
A log with the patients’ name and date of birth will be kept
along with their unique study number in a separate file. All
the data generated from the study will be stored in an
anonymised form in a bespoke database, which will also be
password protected. Only anonymised information will be
stored on this, and participants will only be identifiable by
their study number. All paperwork will be kept in a locked
filing cabinet in a locked office. All the data will be stored
on university server on a password-protected computer
with a limited access to the research team, in accordance
with the NHS and University of Edinburgh guidelines and
in accordance with the Data Protection Act. All study
documentation will be kept for a minimum of 5 years from
the protocol defined end of study point. When the mini-
mum retention period has elapsed, study documentation
will not be destroyed without permission from the sponsor.
The trial statistician will also be blinded to the treatment
during analysis.
Ethics
Ethical approval has been obtained from the Scotland A
Research Ethics Committee (LREC 16/SS/0010).
Dissemination
The data will be presented at international conferences
and published in peer-reviewed journals. The clinical
study report will be used for publication and presentation
at scientific meetings. We will make the information
obtained from the study available to the public through
national bodies, e.g. Endometriosis UK.
Discussion
We believe that a definitive evaluation of the efficacy of
Omega-3 PUFA in the management of endometriosis re-
quires a multicentre randomised controlled trial. Recognising
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that there may be potential difficulties in mounting a large
randomised controlled trial for the management of
endometriosis-associated pain using a supplement which is
widely available over the counter, we have designed this pilot
study to assess practical feasibility following the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials (IMMPACT) recommendations for the design of
chronic pain clinical trials [20]. We plan to randomise partic-
ipants to either Omega-3 PUFA or olive oil and then evaluate
recruitment and retention rates as our primary outcome.
A potential limitation of our study is the broad inclusion
and exclusion criteria which we have produced in an at-
tempt to reflect the true clinical scenario of endometriosis.
Our criteria do not take into account pain intensity, do
not exclude women with non-reproductive comorbidities
(e.g. irritable bowel syndrome, bladder pain syndrome)
that could explain their symptoms and allow participants
the use of concomitant medications. We are aware that
these characteristics may increase variability in patient
responsiveness to treatment and carry the risk of failing to
demonstrate treatment effect. We will therefore capture
this information in our pilot study in the participants’
questionnaires and treatment diaries to inform interpret-
ation of our results and the planning of the future rando-
mised controlled trial. Like many of the medications/
supplements used for endometriosis, Omega-3 PUFA
given in the highest effective dose with the rate and sever-
ity of adverse effects are minimised.
One of the other limitations of our pilot study is the lack
of availability of a suitable placebo. It was not possible to
find a placebo identical to Omega-3 PUFA, and therefore,
we decided to use a ‘comparator’ (olive oil) instead of a
true placebo. We thought that olive oil, a comparator with
the potential for pain relief [21], was the best option for
our target population to encourage participation in our
trial [22]. The drawback of using olive oil is that it may
have a unique taste and there is a theoretical risk of the
subjects guessing which arm of the trial they have been
randomised to. In order to determine whether significant
‘unblinding’ was present, we will ask the subjects at the
conclusion of the trial to guess what treatment was re-
ceived and the primary reason for the guess in an attempt
to determine the validity of using olive oil as a suitable
comparator. Another limitation of our study is the short
timescale of the treatment phase, and we are aware that a
longer trial will likely be necessary to better assess the
long-term effects of Omega-3 PUFA.
We have chosen data collection tools to assess the core
domains of pain, physical/emotional functioning (including
sleeping difficulties), improvement/satisfaction with treat-
ment, symptoms and adverse events, following advice from
a clinical psychologist and a general practitioner, both with
a research interest in endometriosis. These tools are in line
with the IMMPACT recommendations for chronic pain
trials [23]. We will assess the reliability and acceptability of
these data collection tools in order to refine our methods
for the subsequent RCT.
In summary, this pilot trial with embedded evaluation of
trial processes and collection of outcome data will allow
us to undertake detailed feasibility work to inform a future
large-scale trial in the important but challenging area of
dietary supplements and endometriosis-associated pain.
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